CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

June 7, 2022

Study Completion Date

June 7, 2022

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

CSL312

Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody

DRUG

Placebo

Buffer without active ingredient

Trial Locations (28)

1088

Semmelweis University, Budapest

10117

Charité Universitätsmedizin Berlin, Berlin

17033

Pennsylvania State University, Hershey

20815

Institute of Asthma and Allergy, Chevy Chase

35209

Clinical Research Center of Alabama, Birmingham

45231

Bernstein Clinical Research Center LLC, Cincinnati

55131

CRC Clinical Research / Hautklinik und Poliklinik der Universitätsklinik Mainz, Mainz

60590

Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt am Main

64546

HZRM Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf

75231

AARA Research Center, Dallas

85251

Medical Research of Arizona, Scottsdale

90404

Raffi Tachdjian MD, Inc., Santa Monica

94598

Allergy and Asthma Clinical Research, Walnut Creek

7830604

Barzilai University Medical Center, Ashkelon

T6G 2B7

University of Alberta - Research Transition Facility, Edmonton

K1H 1E4

Ottawa Allergy Research Corp, Ottawa

M3B 3S6

Gordon Sussman Clinical Research Inc., Toronto

G1V 4W2

Clinique specialisee en allergie de la Capitale, Québec

04103

Universitätsklinikum Leipzig, Leipzig

734-8551

Hiroshima University Hospital, Hiroshima

'650-0017

Kobe University Hospital, Kobe

216-8511

St.Marianna University School of Medicine Hospital, Kawasaki-shi

350-8550

Saitama Medical Center, Saitama

'849-8501

Saga University Hospital, Saga

425-0088

Koga Community Hospital, Yaizu-shi

113-8431

Juntendo University Hospital, Bunkyo

340-0041

Saiyu Soka Hospital, Saitama

1105 AZ

Amsterdam UMC, Location AMC, Amsterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY